Tag: AVG
Healionics’ STARgraft receives US FDA Breakthrough Device designation
Healionics Corporation has today announced that its STARgraft arteriovenous graft—which it states is designed to provide a safer and more reliable means of bloodstream...
Lutonix AV global registry shows higher target lesion primary patency when...
In a new post-hoc analysis of the Lutonix (BD) arteriovenous (AV) global registry using investigational device exemption (IDE) criteria, Dimitrios Karnabatidis (Patras University Hospital,...
WRAPSODY Arteriovenous Access Efficacy (WAVE) pivotal study completes enrolment
Merit Medical has announced that is has completed enrolment in its WRAPSODY Arteriovenous Access Efficacy (WAVE) pivotal study. Merit’s WAVE study is a prospective,...
“Very encouraging” 12-month data from WRAPSODY FIRST study presented at CIRSE...
Twelve-month results from a first-in-human study of the Wrapsody cell-impermeable endoprosthesis (Merit Medical Systems) for the treatment of access circuit stenosis in haemodialysis patients...
First data from AVeVA suggest Covera stent “safe and effective” at...
Early data from the prospective multicentre AVeVA study that employed a covered stent (Covera; Bard, now BD) to treat stenoses at the venous anastomosis...
Latest data on Lutonix and IN.PACT drug-coated balloons in AV access...
There in an increasing physician interest in exploring the role of drug-coated balloons in arteriovenous (AV) access. At the Leipzig Interventional Course (LINC; 30...
